Skip to main content

Gout

gout.MTP1_.jpg

Black Adults Have a Higher Gout Risk

Aug 15, 2022

In a cross-sectional study of US adults, gout was more prevalent in black adults compared to white adults; possibly explained by sex-specific dietary differences and social determinants of health and clinical factors. 



Population data was derived from survey of 18,693 participants in

Read Article
Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study https://t.co/1fiNgBQUbr looks like lower ab response and drops over 6 mths - boosters important in our patients

Peter Nash @drpnash( View Tweet )

Aug 15, 2022
Gout Flares Up Cardiac Risks A large case-control study showed that gout patients who experienced a cardiovascular (CV) event were more likely to have had a recent (< 120 days) gout flare compared to those without CV events.https://t.co/HVmHZ0Pi7I https://t.co/XhdLTed5mr
Dr. John Cush @RheumNow( View Tweet )
Aug 04, 2022
CV,risk,MI,heart,cardiac

Gout Flares Up Cardiac Risks

Aug 03, 2022

A large case-control study showed that gout patients who experienced a cardiovascular (CV) event were more likely to have had a recent (< 120 days) gout flare compared to those without CV events.



This study sought to investigate the temporal association between gout flares and

Read Article
RheumNow Podcast square

Social Media Questions (7.29.2022)

Jul 29, 2022

Dr. Jack Cush reviews the news, journal reports and rheumatologist cases from the past week on RheumNow.com. This podcast is brought to you by StillsNow.com - be sure to sign up for our monthly StillsNow email and Monthly StillsNow Podcast.




  1. Study of 63 Thalassemia pts (50

Read Article
Metanalysis of cardiovascular effects of Colchicine: 21 RCTs (15,569 pts shows colchicine was superior to placebo reducing CV events; with lower risk recurrent pericarditis (RR 0.50), MACE (RR 0.67), & AFib recurrence (RR 0.68) https://t.co/oQEF7dmkH8 https://t.co/P7IKeZpcUB
Dr. John Cush @RheumNow( View Tweet )
Jul 28, 2022
Have you checked out our new sister-site, Still's Now? A new site for Still's disease, autoinflammatory & febrile disorders.https://t.co/oWEugnOB6k https://t.co/5jwiP2Xqrz
Dr. John Cush @RheumNow( View Tweet )
Jul 26, 2022
Rheums: Got a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.https://t.co/QUTIbK3r89 https://t.co/FZcTLREida
Dr. John Cush @RheumNow( View Tweet )
Jul 22, 2022
Rheumatologist Survey: What do you rely on MOST in diagnosing Still’s disease? Sxs? Labs? Both? Criteria? Fever? Vote here:https://t.co/oANKpKqJA5 https://t.co/LIjRSBHNBi
Dr. John Cush @RheumNow( View Tweet )
Jul 21, 2022
MTX + Pegloticase Combo FDA Approved Horizon has announced that the FDA has approved the expanded labeling of pegloticase (Krystexxa) injection to be co-administered with methotrexate (MTX), to improve response rates in patients with uncontrolled gout.https://t.co/D71dmMuB9B https://t.co/jonfLqQ0lj
Dr. John Cush @RheumNow( View Tweet )
Jul 16, 2022
RheumNow Podcast square

Fever Pitch (7.15.2022)

Jul 15, 2022

Dr. Jack Cush reviews the new studies and drug approvals and new insights into febrile disorders from the past week on RheumNow.com




  1. Ustekinumab (IL-12/23i) phase 2 study was successful in #SLE; but the phase 3 LOTUS study of 512 pts, UST was NOT superior to PBO (SRI-4 44% v

Read Article
FDA.approved.jpg

MTX + Pegloticase Combo FDA Approved

Jul 11, 2022

Horizon has announced that the U.S. Food and Drug Administration (FDA) has approved the expanded labeling of pegloticase (Krystexxa) injection to be co-administered with methotrexate (MTX), to improve response rates in patients with uncontrolled gout.



FDA approval is based on the 

Read Article
renal.stone_.LBP_.jpg

ICYMI: Allopurinol Safety in CKD Patients

Jul 06, 2022

A study in the Annals of Internal Medicine reports chronic kidney disease (CKD) patients can be safely treated with allopurinol without an increased risk of mortality.

Read Article
#EULAR2022 has concluded but you can find all our coverage here https://t.co/s62OVJPQ86 https://t.co/QAvPQYCABj
Dr. John Cush @RheumNow( View Tweet )
Jun 18, 2022
Gout Undertreatment Persists Despite updated gout management guidelines from EULAR and BSR, treatment of gout is suboptimal with regard to the use of urate-lowering therapy (ULT) and normalizing serum uric acid (< 6.0 mg/dl) levels.https://t.co/qW7ZaXbnx3 https://t.co/ZBKIjuQp10
Dr. John Cush @RheumNow( View Tweet )
Jun 10, 2022
gout.toe_.MTP_.jpg

Gout Undertreatment Persists

Jun 08, 2022

Despite updated gout management guidelines from European (EULAR) and British (BSR) societies, treatment of gout is suboptimal with regard to the use of urate-lowering therapy (ULT) and normalizing serum uric acid (< 6.0 mg/dl) levels.



A cohort analysis using UK gout patients (n = 

Read Article
Topical therapies take centre stage Topical treatments have so often been the low level “sure you can try this” option. However there are exciting data that these approaches may become part of our main armamentarium. #EULAR2022 https://t.co/V9plk1vAEd https://t.co/fyNWWtconi
Dr. John Cush @RheumNow( View Tweet )
Jun 06, 2022
ice cubes

Topical therapies take centre stage

Topical treatments have so often been the low level “sure you can try this” option. However there are exciting data that these approaches may become part of our main armamentarium. 

Read Article
gout.MTP1_.jpg

Real World Data on Urate Lowering Therapy

Jun 04, 2022

Urate lowering therapy (ULT) is the backbone therapy for long-term gout treatment and maintenance, but real-world gout management is often imperfect and suboptimal. 

Read Article
#EULAR2022 POS0285 130K UK patients had incident gout bw 2004-2020 ⭐️Only 29% started on ULT w/in 12 mos ⭐️Target urate level only 14% in 2004, only to 17% in 2020 Updated EULAR guidelines in 2016: No statistical difference in ULT Rx or target attainment @Rheumnow
Jun 04, 2022
#EULAR2022 POS0282 Febuxostat vs allopurinol: CV risk population study ⭐️16% reduction in all-cause mortality among febuxostat users, mostly non-CV death reduction ⭐️CV safety non-inferior to allopurinol @Rheumnow https://t.co/1oDSioQWPT
Jun 04, 2022
#EULAR2022 POS0283: Do Rheums have Gout Stigma? ⭐️Stereotypes about pt related factors ⭐️Rheumatologists feel diet, exercise, wt loss more important in gout than RA, pharmacologic therapies less important than RA @Rheumnow
Jun 04, 2022
#EULAR2022 POS0280 Gout is associated with higher mortality in Women ⭐️Higher all cause and CV mortality RR 1.28 risk of mortality in pts without CHD, with gout compared to controls (No CHD or gout) @Rheumnow https://t.co/6o1EKSp2F8
Jun 04, 2022
So what diet to follow with autoimmunity in mind? So many, all with different instructions. Let’s concentrate on where they agree: yes to fruits & vegetables no to emulsifiers & processed foods #EULAR2022 @RheumNow https://t.co/I9abweQOyZ
Jun 03, 2022
Hilarious debate #EULAR2022 between Christian Dejaco and Robert Landewe on whether telemedicine is the future of rheumatology. In amongst the trash talking, here are some highlights @RheumNow
Jun 03, 2022
×